Canaccord Genuity Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $44
Kailera Therapeutics Inc KLRA
$13.85
▲ +1.09%
(+$0.15)
Open
$13.97
Prev Close
$13.70
Day Range
$13.39 – $14.90
52W Range
$9.76 – $28.23
Market Cap
$1.78B
Beta
1.48
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-04-17 |
| Shares Out. | 129,640,000 |
| Website | kailera.com ↗ |
| Phone | 15084409475 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$95.7M |
| Free Cash Flow | -$309.6M |
| Total Assets | $1.08B |
| Total Liabilities | $51.1M |
| Equity | $1.03B |
About Kailera Therapeutics Inc
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Kailera Therapeutics Inc is a publicly traded company under the ticker symbol KLRA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-11-01)